Blood culture negative endocarditis: dire straits for the Heart Team

Last Updated: March 17, 2025


Disclosure: None
Pub Date: Monday, Mar 17, 2025
Author: Cristiane C Lamas, MD MRCP PhD
Affiliation: Instituto Nacional de Cardiologia, and Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, Brazil

Infective endocarditis is a severe condition, with high morbidity and mortality.1-3 Blood culture negative endocarditis is a subset of IE which represents an even more defying scenario, as the practicing physician must treat the patient with antimicrobials which are not directed to an identified pathogen, but rather to possible pathogens. Not surprisingly, BCNE has greater mortality, as reported in the recent predominantly European series of patients included between 2016-2018, wherein patients with culture negative IE (defined as patients with IE with negative blood and tissue cultures) were compared with those with BCPE.4 In this publication, 30- day mortality was 10.2% for 263/2590 patients with BCPE vs 78/523 (14.9%) for those with CNE, and death at 1 year was still significantly different between groups, being 22.5% for BCPE vs 25.8% for CNE. The latter difference between groups did not hold for the subsets of patients who had undergone surgery.4 Other smaller series have also shown greater mortality for BCNE.5-6 Some series have not shown greater mortality but high morbidity, with complicating heart failure being more frequent in BCNE.7-8 For all these reasons, the consensus statement provided by DeSimone and expert colleagues is an important contribution to field. 9

The frequency of BCNE varies geographically, reported as 10% in Europe, 7% in North America, and 20% in South America in the multinational study prospective cohort study from the International Collaboration on Endocarditis group.1 In the years 2000 to 2005, 2781 adults with definite IE were identified, according to the modified Duke criteria.10 More recently, the EURO Endo study reported BCNE in 16.8% of 3116 adult patients;2 similarly, a German study of 521 patients with IE who were operated on from 2013-2020 had a 16.3% rate of BCNE. 11 Since these estimates relate to tertiary centers' data, the conundrums are not so much laboratory resources but clinical practice, especially the prescription of antibiotics and the low suspicion of IE as the cause of an infectious syndrome in the first place, resulting in a late diagnosis.

Although blood cultures usually become positive within 5 days for most culturable microorganisms causing true bacteremia or fungemia,12 incubation times should be prolonged for patients with suspected IE who have negative cultures after 3 days incubation, especially if the patients have prosthetic valve IE or intracardiac devices, as Cutibacterium acnes is a possible agent, and related blood cultures become positive in a median of 7 days (IQR, 6-9 days);13 a recent multicenter retrospective study reported that 54.3% of C.acnes IE was initially BCNE.14 Moreover, if Bartonellae are suspected, based on epidemiological grounds, incubation times need to be extended for up to 3 weeks, though serology will be a quicker means to diagnosis.15

Approximately half the patients with left-side endocarditis undergo operations.1.2 This presents an opportunity for establishing diagnosis in those who have negative blood cultures. Valve culture should be requested, but with the knowledge that they have a low yield, of around 15-41%, especially in those patients who have received more than 2 weeks antimicrobial therapy. 16-19 Furthermore, valve culture results may lead to confusion when organisms such as coagulase negative staphylococci, Acinetobacter, Ralstonia picketti and other non- Pseudomonas aeruginosa non- fermenting rods are grown, as they may represent contaminants picked up during surgery or when manipulating the specimen.16,17 Cell valve cultures have a higher yield, of 45.7% .15 Besides valve culture, histopathology is mandatory and may be especially helpful in centers or countries with fewer resources, as it may confirm the diagnosis of IE and provide clues to its etiology by showing morphological features such as cocci, rods or yeasts in the Brown-Brenn or other stains.20 Cocci on histopathology, unfortunately, are the morphological presentation for staphs, streps and enterococci, but finding rods or yeasts is oftentimes helpful.

Molecular diagnosis of excised valves is a useful tool, as discussed in the statement,9 but is often inaccessible in low- middle- income countries. Besides, a positive PCR from a valvular specimen may represent prior infection, as DNA may persist for months to years in cardiac valves following an adequately treated IE episode.21-23 These findings reinforce the importance of correlating valvular molecular biology results with histopathology of valves. On the other extreme of the spectrum of diagnostic possibilities, a recent study from Germany evaluated excised native or prosthetic valves of patients who had IE and who underwent conventional microbiological culture and fluorescence in situ hybridization combined with 16S rRNA-gene polymerase chain reaction and sequencing (FISHseq), finding that while valve cultures alone identified pathogens in 32% of BCNIE patients, the combination with FISHseq confirmed the infective etiology in 98% and identified causative pathogens in 52%.11

The possible causative microorganisms in BCNE depend on epidemiological issues, for example, the site of acquisition for IE. If the infection was acquired in the community, relevant aspects are features of the place where the patient lives, for example, if it is a rural area, where Coxiella burnetii infection may be seen in farm animals and their products, such as milk, butter, cheese and hides, or even in the dust in the surrounding environment; 24 what the patient does for a living, for example, is he/she a veterinarian, a farmer, does he/she have contact with animals , for example, in a PET shop ; does he/she have any pets at home ( cats are particularly important for B.henselae infection),25 and specifically, have mammal pets given birth in the recent days to weeks (infected mammals' placentas are rich in Coxiella which may aerosolize).24 Other important information in the patient's history is how well the patient looks after his/her oral cavity, whether he/she has been submitted to oral, genitourinary or gastrointestinal procedures in recent days or weeks, whether he/she has been bitten by insects such as mosquitoes, or ticks, or has had piercings, that could serve as portals of entry for skin microbes. 26 Empirical treatment regimens should cover oral streptococci, staphylococci, and enterococci, and less often, the HACEK group; vancomycin and ceftriaxone are appropriate,9 though synergism for enterococci and for patients who harbor prosthetic material will be lacking. Moreover, if Bartonella and Coxiella are suspected, doxycycline may be added empirically, while waiting for serological or molecular biology results.

In health care settings, causative microorganisms often involve staphylococci, but enterococci, (multidrug resistant) Gram negatives and Candida are progressively more frequently reported.27,28 Noteworthily, antibiotic use is common in nosocomial, and health care- associated non- nosocomial settings, and IE acquisition in these scenarios often results from bacteremia or fungemia secondary to central line infections or other infections, such as pneumonia or deep wound site infections. 27,28 These considerations are important regarding empirical antimicrobial therapy for health care-related BCNE. Treating BCNE in patients who have health care-related BCNE will depend on the susceptibility pattern encountered for Gram negatives locally, as ESBL producers are commonly found in this scenario. A frequently used empirical combination therapy is vancomycin and meropenem; the addition of rifampin and/or gentamycin for synergy makes sense for staphylococci, enterococci and Gram negatives. The duration will usually be not less than 6 weeks intravenous therapy for beta lactams and glycopeptides. Fungi should be particularly suspected in patients with large vegetations and frequent recurring embolization despite antibiotic therapy, and antifungal empirical therapy is recommended especially in early prosthetic valve IE.29 In inoperable patients due to unacceptably high surgical risk, oral antimicrobials are often continued for a long period of time, and PET CT scans may be of help in judging when to stop.30,31 However, deciding on the choice of oral antibiotics for possibly resistant unknown pathogens is a nearly impossible task. Besides imaging, metagenomic sequencing may indicate the fall in the microbial counts or even negativity of counts 32, further helping the clinician to decide when antimicrobials suffice.

In summary, BCNE is a niche of IE that deserves careful consideration regarding diagnosis and treatment. The AHA statement contributes to clarify several points and draw the clinicians' attention to this special subset of patients, who need close monitoring and follow up.

Citation


DeSimone DC, Garrigos ZE, Marx GE, Tattevin P, Hasse B, McCormick DW, Hannan MM, Zuhlke LJ, Radke CS, Baddour LM; on behalf of the American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Blood culture–negative endocarditis: a scientific statement from the American Heart Association. J Am Heart Assoc. 2025;14:e040218. DOI: 10.1161/JAHA.124.040218

References


  1. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, et al.; International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009 Mar 9;169(5):463-73. doi: 10.1001/archinternmed.2008.603.
  2. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al.; Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. European heart journal vol. 40,39 (2019): 3222-3232.doi: 10.1093/eurheartj/ehz620.
  3. Abegaz TM, Bhagavathula AS, Gebreyohannes EA, Mekonnen AB, Abebe TB. Short- and long-term outcomes in infective endocarditis patients: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2017 Dec 12;17(1):291. doi: 10.1186/s12872-017-0729-5.
  4. Kong WKF, Salsano A, Giacobbe DR, Popescu BA, Laroche C, Duval X, Schueler R, Moreo A, Colonna P, Piper C, Calvo-Iglesias F, et al . Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry. Eur Heart J. 2022 Aug 1;43(29):2770-2780. doi: 10.1093/eurheartj/ehac307.
  5. Salsano A, Giacobbe DR, Del Puente F, Natali R, Miette A, Moscatelli S, Perocchio G, Scarano F, Porto I, Mariscalco G, Bassetti M, Santini F. Culture-negative infective endocarditis (CNIE): impact on postoperative mortality. Open Med (Wars). 2020 Jun 20;15(1):571-579. doi: 10.1515/med-2020-0193.
  6. Díez-Villanueva P, Muñoz P, Marín M, Bermejo J, de Alarcón González A, Fariñas MC, Gutiérrez-Cuadra M, Pericás Pulido JM, Lepe JA, Castelo L, et al . Infective endocarditis: Absence of microbiological diagnosis is an independent predictor of inhospital mortality. Int J Cardiol. 2016 Oct 1;220:162-5. doi: 10.1016/j.ijcard.2016.06.129.
  7. Ferrera C, Vilacosta I, Fernández C, López J, Olmos C, Sarriá C, Revilla A, Vivas D, Sáez C, Rodríguez E, San Román JA. Reassessment of blood culture-negative endocarditis: its profile is similar to that of blood culture-positive endocarditis. Rev Esp Cardiol (Engl Ed). 2012 Oct;65(10):891-900.
  8. Lamas CC, Fournier PE, Zappa M, Brandão TJ, Januário-da-Silva CA, Correia MG, Barbosa GI, Golebiovski WF, Weksler C, Lepidi H, Raoult D. Diagnosis of blood culture-negative endocarditis and clinical comparison between blood culture-negative and blood culture-positive cases. Infection. 2016 Aug;44(4):459-66. doi: 10.1007/s15010-015-0863-x.
  9. De Simone et al 2025.
  10. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al.; Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000 Apr;30(4):633-8. doi: 10.1086/313753.
  11. Grubitzsch H, Puritz JE, Greve D, Biefer HRC, Von Schöning D, Kikhney J, Moter A, Sima ST, Schneider-Reigbert M, Stegemann MS, Pfäfflin F, Falk V. Surgery for blood culture-negative infective endocarditis: outcomes and the role of molecular biological imaging as diagnostic approach. Eur J Cardiothorac Surg. 2024 Dec 16: ezae453. doi: 10.1093/ejcts/ezae453.
  12. Wilson ML, Mirrett S, Reller LB, Weinstein MP, Reimer LG. Recovery of clinically important microorganisms from the BacT/Alert blood culture system does not require testing for seven days. Diagn Microbiol Infect Dis. 1993 Jan;16(1):31-4. doi: 10.1016/0732-8893(93)90127-s.
  13. Heinen FJ, Arregle F, van den Brink FS, Ajmone Marsan N, Bernts L, Houthuizen P, Kamp O, Roescher N, Timmermans N, Verkaik N, Roos-Hesselink J, Post MC, Habib G, Tanis W. Clinical Characteristics and Outcomes of Patients with Cutibacterium acnes Endocarditis. JAMA Netw Open. 2023 Jul 3;6(7): e2323112. doi: 10.1001/jamanetworkopen.2023.23112.
  14. Saha S, Joskowiak D, Marin-Cuartas M, De La Cuesta M, Weber C, Luehr M, Petrov A, Dzilic E, Sandoval-Boburg R, Marinos SL, Pfeiffer P, Horke KM, Schnackenburg P, Hertel N, Awad G, Wacker M, Moter I, Caldonazo T, Kyashif T, Petersen J, Sill B, Moter A, Eichinger W, Reichenspurner H, Dohle D, Popov AF, Krane M, Matschke K, Wahlers T, Doenst T, Borger M, Misfeld M, Hagl C. Cutibacterium acnes infective endocarditis-an emerging pathogen. Eur J Cardiothorac Surg. 2024 Nov 28;66(6): ezae422. doi: 10.1093/ejcts/ezae422.
  15. Muñoz P, Bouza E, Marín M, Alcalá L, Rodríguez Créixems M, Valerio M, Pinto A; Group for the Management of Infective Endocarditis of the Gregorio Marañón Hospital. Heart valves should not be routinely cultured. J Clin Microbiol. 2008 Sep;46(9):2897-901. doi: 10.1128/JCM.02173-07.
  16. Fournier PE, Thuny F, Richet H, Lepidi H, Casalta JP, Arzouni JP, et al. Comprehensive diagnostic strategy for blood culture-negative endocarditis: a prospective study of 819 new cases. Clin Infect Dis. 2010 Jul 15;51(2):131-40. doi: 10.1086/653675.
  17. Brandão TJ, Januario-da-Silva CA, Correia MG, Zappa M, Abrantes JA, Dantas AM, Golebiovski W, Barbosa GI, Weksler C, Lamas CC. Histopathology of valves in infective endocarditis, diagnostic criteria and treatment considerations. Infection. 2017 Apr;45(2):199-207. doi: 10.1007/s15010-016-0953-4.
  18. Halavaara M, Martelius T, Järvinen A, Antikainen J, Kuusela P, Salminen US, Anttila VJ. Impact of pre-operative antimicrobial treatment on microbiological findings from endocardial specimens in infective endocarditis. Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):497-503. doi: 10.1007/s10096-018-03451-5
  19. Armstrong C, Kuhn TC, Dufner M, Ehlermann P, Zimmermann S, Lichtenstern C, Soethoff J, Katus HA, Leuschner F, Heininger A. The diagnostic benefit of 16S rDNA PCR examination of infective endocarditis heart valves: a cohort study of 146 surgical cases confirmed by histopathology. Clin Res Cardiol. 2021 Mar;110(3):332-342. doi: 10.1007/s00392-020-01678-x.
  20. Lepidi H, Durack DT, Raoult D. Diagnostic methods current best practices and guidelines for histologic evaluation in infective endocarditis. Infect Dis Clin North Am. 2002 Jun;16(2):339-61, ix. doi: 10.1016/s0891-5520(02)00005-3.
  21. Casalta JP, Thuny F, Fournier PE, Lepidi H, Habib G, Grisoli D, et al. DNA persistence and relapses questions on the treatment strategies of Enterococcus infections of prosthetic valves. PLoS One. 2012;7(12): e53335
  22. Rovery C, Greub G, Lepidi H, Casalta JP, Habib G, Collart F, Raoult D. PCR detection of bacteria on cardiac valves of patients with treated bacterial endocarditis. J Clin Microbiol. 2005 Jan;43(1):163-7. doi: 10.1128/JCM.43.1.163-167.2005.
  23. Lang S, Watkin RW, Lambert PA, Littler WA, Elliott TS. Detection of bacterial DNA in cardiac vegetations by PCR after the completion of antimicrobial treatment for endocarditis. Clin Microbiol Infect. 2004 Jun;10(6):579-81. doi: 10.1111/j.1198-743X.2004.00821. x.
  24. Stein A, Raoult D. Q fever endocarditis. Eur Heart J. 1995 Apr;16 Suppl B:19-23. doi: 10.1093/eurheartj/16.suppl_b.19.
  25. Maurin M, Birtles R, Raoult D. Current knowledge of Bartonella species. Eur J Clin Microbiol Infect Dis. 1997 Jul;16(7):487-506. doi: 10.1007/BF01708232.
  26. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. doi: 10.1161/CIR.0000000000000296.
  27. Yu KC, Jung M, Ai C. Characteristics, costs, and outcomes associated with central-line-associated bloodstream infection and hospital-onset bacteremia and fungemia in US hospitals. Infect Control Hosp Epidemiol. 2023 Dec;44(12):1920-1926. doi: 10.1017/ice.2023.132.
  28. Tabah A, Buetti N, Staiquly Q, Ruckly S, Akova M, Aslan AT, et al; EUROBACT-2 Study Group, ESICM, ESCMID ESGCIP and the OUTCOMEREA Network. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study. Intensive Care Med. 2023 Feb;49(2):178-190. doi: 10.1007/s00134-022-06944-2.
  29. vMeena DS, Kumar D, Agarwal M, Bohra GK, Choudhary R, Samantaray S, Sharma S, Midha N, Garg MK. Clinical features, diagnosis and treatment outcome of fungal endocarditis: a Systematic review of reported cases. Mycoses. 2022; 65:294-302. doi: 10.1111/myc.13398
  30. Bucy L, Erpelding ML, Boursier C, Lefevre B, Alauzet C, Liu Y, Chevalier E, Huttin O, Agrinier N, Selton-Suty C,. Real world experience of therapeutic monitoring of medically treated prosthetic valve infective endocarditis by 18F-FDG-PET/CT. J Nucl Cardiol. 2023 Oct;30(5):2096-2103. doi: 10.1007/s12350-023-03339-8.
  31. Régis C, Thy M, Mahida B, Deconinck L, Tubiana S, Iung B, Duval X, Rouzet F. Absence of infective endocarditis relapse when end-of-treatment fluorodeoxyglucose positron emission tomography/computed tomography is negative. Eur Heart J Cardiovasc Imaging. 2023 Oct 27;24(11):1480-1488. doi: 10.1093/ehjci/jead138
  32. Eichenberger EM, Degner N, Scott ER, Ruffin F, Franzone J, Sharma-Kuinkel B, Shah P, Hong D, Dalai SC, Blair L, et al. Microbial Cell-Free DNA Identifies the Causative Pathogen in Infective Endocarditis and Remains Detectable Longer Than Conventional Blood Culture in Patients with Prior Antibiotic Therapy. Clin Infect Dis. 2023 Feb 8;76(3): e1492-e1500. doi: 10.1093/cid/ciac426.

Science News Commentaries

View All Science News Commentaries

-- The opinions expressed in this commentary are not necessarily those of the editors or of the American Heart Association --